MedTrace Logo

Treatment Response in Schizophrenia: Bridging Imaging and Postmortem Studies

NCT00937716 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2021-07-26

No results posted yet for this study

Summary

The overarching goal is to identify imaging markers that will predict treatment response, and to confirm or validate these biomarkers using anatomical studies of postmortem tissue. Early detection of drug response would yield specific treatment strategies that are tailored to the individual, thus improving both the quality of life of the patients and drastically reducing the costs associated with unsuccessful treatment strategies.

Conditions

Sponsors & Collaborators

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Adrienne C Lahti, MD · University of Alabama at Birmingham, Department of Psychiatry

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2020-12-31
Completion
2021-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00937716 on ClinicalTrials.gov